恒瑞医药：HRS-5346片被纳入突破性治疗品种名单

Core Viewpoint - The company’s subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has had its HRS-5346 tablets included in the list of breakthrough therapeutic varieties by the National Medical Products Administration, indicating significant progress in its development [1] Group 1: Product Development - HRS-5346 is an oral small molecule inhibitor targeting elevated lipoprotein(a) [Lp(a)] levels, which is a common single-gene lipid disorder and a typical manifestation of lipoprotein dysregulation [1] - Currently, there are no similar products approved for market release domestically or internationally, highlighting the uniqueness of HRS-5346 [1] Group 2: Financial Investment - The cumulative research and development investment for the HRS-5346 project has reached approximately 76.3 million yuan (unaudited) [1]